High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma

Anjan Thakurta, Maria Ortiz, Pedro Blecua, Fadi Towfic, Jill Corre, Natalya V. Serbina, Erin Flynt, Zhinuan Yu, Zhihong Yang, Antonio Palumbo, Meletios A. Dimopoulos, Norma C. Gutierrez, Hartmut Goldschmidt, Pieter Sonneveld, Herve Avet-Loiseau

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Deletions of chromosome 17p (del17p) that span the TP53 gene are associated with poor outcome in multiple myeloma (MM), but the prognostic value of del17p cancer clonal fraction (CCF) remains unclear. We applied uniform cytogenetic assessments in a large cohort of newly diagnosed MM (NDMM) patients carrying varying levels of del17p. Incremental CCF change was associated with shorter survival, and a robust CCF threshold of 0.55 was established in discovery and replication data sets. After stratification on the 0.55-CCF threshold, high-risk patients had statistically significantly poorer outcomes compared with low-risk patients (median progression-free survival [PFS] and overall survival [OS], 14 and 32 vs 23.1 and 76.2 months, respectively). Analyses of a third data set comprising whole-exome sequencing data from NDMM patients identified presence of TP53 deletions/mutations as a necessary requirement for high-risk stratification in addition to exceeding the del17p CCF threshold. Meta-analysis conducted across 3 data sets confirmed the robustness of the CCF threshold for PFS and OS. Our analyses demonstrate the feasibility of fluorescence in situ hybridization– and sequencing-based methods to identify TP53 deletions, estimate CCF, and establish that both CCF threshold of 0.55 and presence of TP53 deletion are necessary to identify del17p-carrying NDMM patients with poor prognosis.
Original languageEnglish
Pages (from-to)1217-1221
JournalBlood
Volume133
Issue number11
DOIs
Publication statusPublished - 14 Mar 2019
Externally publishedYes

Cite this